Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 278

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 278
---
 previously accrued, but unpaid compensation The grant date fair value of the stock options and RSUs totaled $ 60,000, resulting a $ 40,000gain, which is included other income in the accompanying 2024 statement of operations.

Note 4 – Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following:

Schedule of Accounts Payable and Accrued Expenses

|                                       |     |   | September 
       30, 
      2025 |     |   | December 
 31, 2024 |
|:--------------------------------------|:----|:--|----------:|:----|:--|---------:|
| Accounts                              
 payable                               |     | $ |   367,391 |     | $ |  278,676 |
| Professional                          
 fees                                  |     |   |    45,509 |     |   |   40,271 |
| License                               
 fee                                   |     |   |    56,250 |     |   |   75,000 |
| Credit                                
 cards                                 |     |   |     9,202 |     |   |    2,536 |
| Total                                 
 accounts payable and accrued expenses |     | $ |   478,352 |     | $ |  396,483 |

Accrued compensation of $ 1,849,052and $ 1,415,093as of September 30, 2025 and December 31, 2024, respectively, includes amounts due to certain executives and board fees. Prior to the effectiveness of the Company’s IPO, in order to conserve cash, certain executives agreed to defer payment for compensation earned, which was accrued. Upon the completion of the initial public offering in December 2024, the Company resumed paying the executives for compensation as it was earned. The Company will make payments to reduce the balance of accrued compensation, but only in the event the Company has available cash to do so without otherwise negatively impacting the Company’s business plans.

On July 2, 2025, the Compensation Committee of the Board of Directors (the “Compensation Committee”) approved the grant of an aggregate of 357,448stock options issued to certain executives with an exercise price equal to the closing price of the Company’s Common Stock on the grant date, a ten-year term, and which vest in equal annual installments over a three-year period, subject to continued employment. In addition, the Compensation Committee approved cash bonuses totaling $